^
Association details:
| Biomarker: | MET amplification + MET exon 14 mutation + EGFR exon 20 insertion |
|---|---|
| Cancer: | Lung Adenocarcinoma |
| Drug: | Xalkori (crizotinib) (ALK inhibitor) |
| Direction: | Sensitive |
Evidence:
Source:
Title:
A lung adenocarcinoma patient with co-mutations of MET and EGFR exon20 insertion responded to crizotinib
Published date:
06/23/2022
Excerpt:
A 69-year-old male with a right lung adenocarcinoma (T4N2M0, IIIB) was confirmed to be positive for MET exon 14 skipping (c.3028_3028+1delGGinsTT, 44.4%), MET amplification (copy number 4.4), and EGFR exon 20 insertion (p. N771_H773dup, 22.1%) mutations....the patient was subsequently accepted treatment with Crizotinib (250 mg twice a day) and achieved an important clinical remission for six months until the development of brain metastases.
DOI:
https://doi.org/10.1186/s12920-022-01291-z
